Oblique Therapeutics
  • Home Page
  • About us
    • Overview
    • Organization
  • Technology
    • AbiprotTM-antibody platform
    • Abiprot SelectTM
  • Portfolio
    • Overview
    • OT-1096 in TNBC
    • aTRPV1 & aTRPA1 in pain
    • aKRAS in colorectal cancer
    • Collaborations in type 2 diabetes
  • Corporate Gouvernance
    • General annual meetings
    • Board of Directors and Management
  • Investors Relations
    • Reports
  • News
    • Press Releases
    • Publications, conferences & press
  • Contact
Oblique Therapeutics > News > News
  • Home Page
  • About us
    • Overview
    • Organization
  • Technology
    • AbiprotTM-antibody platform
    • Abiprot SelectTM
  • Portfolio
    • Overview
    • OT-1096 in TNBC
    • aTRPV1 & aTRPA1 in pain
    • aKRAS in colorectal cancer
    • Collaborations in type 2 diabetes
  • Corporate Gouvernance
    • General annual meetings
    • Board of Directors and Management
  • Investors Relations
    • Reports
  • News
    • Press Releases
    • Publications, conferences & press
  • Contact

News

Archive
  • November 2020
  • October 2020
  • September 2020
  • June 2020
  • November 2019
  • October 2019
  • July 2019
  • March 2019
  • January 2019
  • November 2018
  • October 2018
  • September 2018
Categories
  • Company updates
  • News
18 Nov 2020

Oblique Therapeutics AB, raises 98 MSEK in a private placement investment round.

19 Oct 2020

This is our first Abiprot patent. We hope that many more will follow.

08 Oct 2020

Oblique Therapeutics AB together with collaborators at Sahlgrenska University Hospital (Gothenburg) and Karolinska Institutet (Stockholm) has been granted 5MSEK by Vinnova to develop neutralizing antibodies towards SARS-CoV-2 and to develop its Abiprot platform into a first-line-of-defence for future pandemics.

21 Sep 2020

24th Sept 2020 – Oblique Therapeutics is delighted to be invited to speak at “Biopharma Conclave 2020”

14 Sep 2020

Oblique Therapeutics is honored to participate as speaker to the 2nd Edition RAS- Targeted Drug Development Congress 15th September 2020

29 Jun 2020

New Press Release-Oblique Therapeutics and Targovax enter collaboration to target mutant RAS cancers by combining their ONCOS and Abiprot™ platforms

24 Oct 2019

Oblique will be presenting at the RAS-Targeted Drug Discovery Europe Summit in February

10 Oct 2019

Oblique Therapeutics is on EU-Startups top 10 list -“10 European biotech startups to look out for in 2019 and beyond”

  • «
  • 1
  • 2
  • 3
  • »
Oblique Therapeutics

Copyright © 2021 Oblique Therapeutics AB.

Contact

Oblique Therapeutics AB
info@obliquet.com

Gothenburg
Arvid Wallgrens Backe 20
413 46 Göteborg
Sweden

Stockholm
Döbelnsgatan 64
113 52 Stockholm
Sweden

Menu
  • Home Page
  • About us
    • Overview
    • Organization
  • Technology
    • AbiprotTM-antibody platform
    • Abiprot SelectTM
  • Portfolio
    • Overview
    • OT-1096 in TNBC
    • aTRPV1 & aTRPA1 in pain
    • aKRAS in colorectal cancer
    • Collaborations in type 2 diabetes
  • Corporate Gouvernance
    • General annual meetings
    • Board of Directors and Management
  • Investors Relations
    • Reports
  • News
    • Press Releases
    • Publications, conferences & press
  • Contact
About

Oblique Therapeutics is a privately held Swedish biotech developing innovative new medicines for severe diseases with a large unmet medical need focusing on pain, and advanced cancer.  The company uses AbiprotTM, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. 

Till toppen

We use cookies to improve the user experience on Oblique Therapeutics. Read more about Cookies

Approve